Novartis (NVS) Reports In-Line Q3 EPS of $1.21; Guides FY15 Sales Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Novartis (NVS) Receives FDA Approval for Afinitor Disperz Labeling Amendment
January 26, 2015 2:17 PM ESTNovartis (NYSE: NVS) received FDA approval of a labeling revision for Afinitor Disperz (everolimus).
In a letter to Novartis (which is embedded below), the FDA stated: This Prior Approval supplemental new drug application revises the ADVERSE REACTIONS, Clinical Study Experience in Renal Angiomyolipoma with... More
